GURU.Markets stock price, segment price, and overall market index valuation
The company's share price TNYA
Tenaya Therapeutics is a biotech company specializing in gene therapy for heart disease. Its stock price represents a venture bet on a breakthrough in this complex field. The chart reflects high volatility and dependence on news from the lab and clinical trials.
Share prices of companies in the market segment - Heart
Tenaya Therapeutics is a biotech company focused on developing gene therapy and other advanced treatments for cardiovascular diseases. We've categorized it as a "Heart" company. The chart below shows how investors value companies working on breakthroughs in cardiology.
Broad Market Index - GURU.Markets
Tenaya Therapeutics is a biotech company focused on developing gene therapy and other advanced cardiovascular treatments. It is a component of the GURU.Markets index. The chart below represents the market. See how this stock compares to the biotech sector.
Change in the price of a company, segment, and market as a whole per day
TNYA - Daily change in the company's share price TNYA
For Tenaya, a cardiac gene therapy company, change_co is a measure of innovation volatility. Daily fluctuations reflect news about clinical trials and technological breakthroughs. This metric forms the basis for biotech company analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Heart
Tenaya Therapeutics, Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with TNYA, which focuses on cardiac gene therapy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Tenaya Therapeutics is a biotech company developing gene therapy for heart disease. Its shares are a bet on a scientific breakthrough, and their high volatility is driven by research news. These movements are part of a broader market where high risks and high hopes intertwine.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization TNYA
For Tenaya Therapeutics, year-over-year performance is a story about developing gene therapy for heart disease. Its 12-month market cap depends entirely on progress in clinical trials. Every successful step confirms the potential of its platform to develop drugs that can not just treat, but cure heart disease.
Annual dynamics of market capitalization of the market segment - Heart
Tenaya Therapeutics, Inc. is a biotech company developing gene therapies for the treatment of cardiovascular diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks inherent in this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tenaya Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new gene therapy trials for heart disease. The company's stock chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization TNYA
Tenaya, a gene therapy company, is a speculative company. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials of its cardiovascular drugs, the success of which will determine its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Heart
Tenaya Therapeutics is a biotech company developing gene therapy for cardiovascular disease. This is one of the most complex and ambitious areas in medicine. The chart below reflects investor confidence in the revolutionary potential of gene therapy for the heart, as well as the high risks associated with such developments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tenaya Therapeutics is at the forefront of the fight against heart disease, developing cutting-edge gene therapies and drugs. The company's future depends solely on the success of its clinical trials. The broader market chart serves as a mere backdrop to demonstrate how scientific news and development milestones have given its stock a life of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization TNYA
Tenaya Therapeutics is a clinical-stage biotech company developing gene therapy for heart disease. Its weekly stock price is highly volatile and depends entirely on news about preclinical and clinical trials.
Weekly dynamics of market capitalization of the market segment - Heart
Tenaya Therapeutics is an early-stage biotech developing gene therapy for heart disease. Its stock is driven by research news, not market trends. The chart clearly shows how out of sync its weekly performance is with the overall healthcare sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Tenaya Therapeutics is an early-stage biotech company working in gene therapy. Its shares are buoyed by anticipation of research results. This chart clearly demonstrates how much its performance is driven by scientific news rather than general market trends.
Market capitalization of the company, segment and market as a whole
TNYA - Market capitalization of the company TNYA
Tenaya Therapeutics' market capitalization reflects investor hopes for its cutting-edge approaches to treating heart disease through gene therapy and regenerative medicine. Its volatile price, typical of biotech, is driven by lab news. The company's valuation is a bet on a scientific breakthrough in one of the most complex areas of medicine.
TNYA - Share of the company's market capitalization TNYA within the market segment - Heart
Tenaya Therapeutics is a clinical-stage biotech developing gene therapy for heart disease. Its market share currently reflects only potential. Its market cap is a venture capital bet that its cutting-edge science will lead to breakthrough drugs.
Market capitalization of the market segment - Heart
Here's a chart showing the biotech sector's market capitalization, and Tenaya Therapeutics is a player in it, focused on treating heart disease with gene therapy. The potential of this market is enormous. Tenaya's stock performance against this backdrop tells a story of high stakes and the hope that its cutting-edge science can conquer heart disease.
Market capitalization of all companies included in a broad market index - GURU.Markets
Tenaya Therapeutics is a biotech company developing gene therapy and other treatments for heart disease. Its market capitalization represents the promise of a breakthrough in cardiology. The chart below shows the economic weight of companies working at the forefront of heart disease treatment.
Book value capitalization of the company, segment and market as a whole
TNYA - Book value capitalization of the company TNYA
Tenaya Therapeutics' foundation is its scientific platform for gene therapy and regenerative medicine, aimed at combating heart disease. Its book value represents capital for preclinical and clinical trials. The chart tells the story of how the biotech company invests in breakthrough but capital-intensive technologies.
TNYA - Share of the company's book capitalization TNYA within the market segment - Heart
Tenaya Therapeutics is developing gene therapy for heart disease. The chart shows its share of actual R&D assets. These include its cutting-edge laboratories and, potentially, pilot production facilities where drugs capable of transforming cardiology are being created.
Market segment balance sheet capitalization - Heart
Tenaya Therapeutics is a biotech company whose value is locked into its scientific platform. It's a classic capital-light business. The chart below reflects the capital intensity of the pharmaceutical sector, highlighting its R&D-focused model.
Book value of all companies included in the broad market index - GURU.Markets
Tenaya Therapeutics is developing gene therapy for heart disease. Its assets include laboratories and research capital. A modest stake in BCap_All represents a material outpost at the forefront of science, aimed at creating breakthrough treatments for one of the leading causes of death.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - TNYA
Tenaya Therapeutics is a gene therapy company. Its book value is its cash flow. Its entire market capitalization is a premium on hope, investors' bet that its cutting-edge science will create the first cure for genetic heart diseases.
Market to book capitalization ratio in a market segment - Heart
Tenaya Therapeutics is a biotech company developing gene therapy for heart disease. Its value is based almost entirely on its scientific potential. The chart shows the huge premium to book value that investors are paying for the hope of developing breakthrough drugs.
Market to book capitalization ratio for the market as a whole
Tenaya Therapeutics is a biotech company developing gene therapy for heart disease. Its market capitalization is based solely on its scientific potential. This chart clearly demonstrates the extreme premium the market places on breakthrough medical technologies compared to the market average.
Debts of the company, segment and market as a whole
TNYA - Company debts TNYA
Tenaya Therapeutics, a biotech company focused on gene therapy for heart disease, is raising capital to fund its cutting-edge research. The debt burden reflects the enormous costs of preclinical and clinical trials required to turn breakthrough science into a viable treatment.
Market segment debts - Heart
Tenaya Therapeutics is a biotech company developing gene therapy for heart disease. This is a cutting-edge, but highly capital-intensive, field of research. This chart allows you to evaluate the company's financial model: whether it relies solely on equity capital, as is common in the sector, or whether it uses debt to support its developments.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio TNYA
Tenaya Therapeutics is a biotech company working on gene therapy for heart disease. This process requires massive investments in R&D over many years. This chart shows how much the company finances its research with debt, allowing us to assess its financial risks on the road to drug approval.
Market segment debt to market segment book capitalization - Heart
Tenaya Therapeutics is a biotech company focused on gene therapy for heart disease. This chart shows debt trends in the sector. It allows one to assess how the company finances its cutting-edge, yet extremely expensive, research and how its financial model, dependent on the success of clinical trials, compares to the industry.
Debt to book value of all companies in the market
Tenaya Therapeutics is a biotech company focused on developing gene therapies for heart disease. While in clinical development, these companies are typically financed through equity rather than debt. This market debt chart clearly demonstrates how Tenaya's financial strategy differs from that of mature, profitable companies with access to credit.
P/E of the company, segment and market as a whole
P/E - TNYA
Tenaya Therapeutics is a biotech company developing gene therapy for cardiovascular disease. This chart reflects investors' high hopes for a scientific breakthrough, not current profits. The company's valuation is a pure bet that its innovative approaches will revolutionize heart disease treatment.
P/E of the market segment - Heart
This industry chart for biotech companies provides key context for Tenaya Therapeutics. It reflects generally high valuations based on hopes for a breakthrough. Comparisons with this chart help understand whether Tenaya's focus on gene therapy for heart disease is considered more or less promising than that of biotechs working in other areas.
P/E of the market as a whole
Tenaya Therapeutics is a biotech company developing gene therapies for cardiovascular diseases, one of the most complex and promising areas of medicine. This graph of investors' overall risk appetite shows whether they are willing to fund Tenaya's extremely expensive and time-consuming research in hopes of a future breakthrough.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company TNYA
Tenaya Therapeutics is a clinical-stage biotech company focused on developing gene therapy for heart disease. This chart reflects speculative investor expectations. The valuation is almost entirely dependent on confidence in the success of its scientific developments, clinical trial results, and potential to transform approaches to heart disease treatment.
%20P%2FE%20TNYA&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-TNYA&v=1772646780342 "Chart of the company's future (projected) P/E TNYA")
Future (projected) P/E of the market segment - Heart
Tenaya Therapeutics is a biotech company focused on developing gene therapies and other treatments for cardiovascular diseases. This chart reflects investor expectations for the company's profitability relative to the sector. It provides an insight into the market's confidence in its scientific platform and potential for developing breakthrough drugs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Heart&v=1772646780356 "Future (projected) P/E graph of the market segment - Heart")
Future (projected) P/E of the market as a whole
Tenaya Therapeutics is a biotech company focused on developing gene therapies for the treatment of heart disease. For a clinical-stage company like Tenaya, this market risk appetite curve is vital. During periods of optimism, investors are more willing to fund cutting-edge research with a long horizon for commercialization.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772646780373 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit TNYA
Tenaya Therapeutics is a biotech company developing gene therapy for heart disease. This is cutting-edge science, requiring significant investment in research. This chart shows the company's financial health during the long journey from laboratory discovery to potential commercial product.
Profit of companies in the market segment - Heart
Tenaya Therapeutics is a biotech company developing gene therapies for the treatment of heart disease. This chart shows the profitability of the cardiac innovation sector. For TNYA, this reflects investors' faith in breakthrough technologies. Their success depends on scientific advances in one of the most complex areas of medicine.
Overall market profit
Tenaya Therapeutics is a biotech company at the forefront of the fight against cardiovascular disease through gene therapy. This is an area with enormous potential, but also high risks. The company's success depends on scientific breakthroughs and clinical trial results, not on the general economic cycles shown in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company TNYA
Tenaya Therapeutics is a clinical-stage biotechnology company focused on developing gene therapies for the treatment of heart disease. The earnings forecast presented here is speculative and reflects analysts' expectations for successful clinical trial results. Any news regarding its developments could dramatically alter these expectations.
%20profit%20of%20the%20company%20TNYA&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-TNYA&v=1772646780444 "Graph of future (projected) profit of the company TNYA")
Future (predicted) profit of companies in the market segment - Heart
Tenaya Therapeutics is a biotech company developing gene therapy for heart disease. The revenue forecast for this cutting-edge segment depends on scientific breakthroughs and successful clinical trials. This chart reflects analysts' collective belief in the commercial potential of gene therapy as a treatment for heart disease.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Heart&v=1772646780464 "Graph of future (predicted) profits of companies in a market segment - Heart")
Future (predicted) profit of the market as a whole
Tenaya Therapeutics is a clinical-stage biotech developing gene therapy for heart disease. Its future depends on the success of its research and raising capital. The market profit forecasts shown here reflect the overall risk appetite of investors, which is critical for funding such companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772646780509 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - TNYA
Tenaya Therapeutics is a biotech company developing gene therapy for heart disease. This chart shows a high speculative valuation without significant revenue. Investors are betting on its scientific platform and potential to develop treatments for previously incurable heart diseases, evaluating future prospects rather than current performance.
P/S market segment - Heart
Tenaya Therapeutics is a biotech company developing gene therapies and other advanced cardiovascular treatments. This is an area with enormous potential. This chart reflects the average revenue estimate for the sector, which helps us understand the high expectations investors have for Tenaya's scientific platform and future drugs.
P/S of the market as a whole
Tenaya Therapeutics is a biotech company developing gene therapies and other treatments for cardiovascular diseases. The company is in early-stage clinical trials. This chart provides a general market backdrop for assessing investor sentiment toward high-risk but potentially breakthrough medical technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company TNYA
Tenaya Therapeutics is a biotech company focused on developing gene therapy for heart disease. This chart shows how the market values the company relative to its future, currently hypothetical, revenues. It reflects the enormous hopes for a breakthrough in treating heart disease at the genetic level.
%20P%2FS%20TNYA&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-TNYA&v=1772646780812 "The graph of the company's future (projected) P/S TNYA")
Future (projected) P/S of the market segment - Heart
Tenaya Therapeutics is a biotech company using gene therapy to treat cardiovascular diseases. Its valuation is based entirely on the potential of its scientific platform. This chart reflects investors' high expectations for its ability to develop breakthrough treatments for one of the most common causes of death.
%20P%2FS%20market%20segment%20graph%20-%20Heart&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Heart&v=1772646780899 "Future (projected) P/S market segment graph - Heart")
Future (projected) P/S of the market as a whole
Tenaya Therapeutics is a clinical-stage biotech company focused on gene therapy for heart disease. Their survival and success depend on research funding. This market optimism curve is vital for TNYA. Only during periods of investor confidence in the future is capital flowing into such risky and long-term projects possible.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772646780928 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales TNYA
Tenaya Therapeutics is a cutting-edge biotech company developing gene therapies for the treatment of heart disease. Being in the clinical stage, the company does not yet have commercial products and its revenue is minimal. This timeline will reflect its ability to bring revolutionary heart disease treatments to market.
Sales of companies in the market segment - Heart
Tenaya Therapeutics is a biotech company using cutting-edge approaches, including gene therapy and cellular regeneration, to combat heart disease. Their goal is to find cures, not just symptom management. While in the research stage, the company is not yet revenue-generating, but is building the foundation for future breakthroughs.
Overall market sales
Tenaya Therapeutics is a biotech company developing gene therapies for cardiovascular disease. Its goal is to create drugs that can halt or reverse the disease. This revenue chart includes the healthcare sector, where TNYA operates at the forefront of science, striving to achieve breakthroughs in treating one of the leading causes of death.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company TNYA
Tenaya Therapeutics is a biotech company developing gene therapy and small molecule drugs for the treatment of cardiovascular diseases. This chart reflects analysts' speculative expectations for the success of its clinical programs and the potential for breakthrough treatments for heart disease.
%20sales%20of%20the%20company%20TNYA&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-TNYA&v=1772646781029 "Schedule of future (projected) sales of the company TNYA")
Future (projected) sales of companies in the market segment - Heart
Tenaya Therapeutics is a biotech company developing gene therapy for cardiovascular diseases. This chart shows forecasts for the cutting-edge yet promising gene therapy market. It illustrates expert expectations for scientific progress and future demand for revolutionary genetic treatments for heart disease.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Heart&v=1772646781073 "Schedule of future (projected) sales of companies in the market segment - Heart")
Future (projected) sales of the market as a whole
Tenaya Therapeutics, a biotech company focused on treating heart disease, sees this chart as a reflection of the investment climate in knowledge-intensive industries. The stable economic growth predicted here ensures an influx of capital into biotech, necessary for costly research and clinical trials of gene therapy.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772646781094 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality TNYA
Tenaya Therapeutics is a biotech company developing gene therapy for heart disease. It is in clinical trials and does not yet have any commercial products. This chart doesn't reflect profits, but rather the intensity of its investment in science and R&D—essentially, the cost of developing future breakthrough drugs that could radically change its financial position.
Market segment marginality - Heart
Tenaya Therapeutics is a biotech company using gene therapy and molecular medicine to treat heart disease. This graph reflects the enormous potential of its scientific platform. A strong operating result will confirm the success of its developments and its potential to transform approaches to heart disease treatment.
Market marginality as a whole
#VALUE!
Employees in the company, segment and market as a whole
Number of employees in the company TNYA
Tenaya Therapeutics is a biotech company focused on developing gene therapies for the treatment of heart disease. This chart shows a small but rapidly growing team of leading scientists and researchers. Their work is at the forefront of science and could lead to breakthrough treatments capable of restoring heart muscle.
Share of the company's employees TNYA within the market segment - Heart
Tenaya Therapeutics is a biotech company at the forefront of gene therapy and regenerative medicine for the treatment of heart disease. Developing such breakthrough treatments requires an elite team of geneticists and cardiologists. This graph illustrates the concentration of unique scientific talent needed to address one of the most complex challenges in medicine.
Number of employees in the market segment - Heart
Tenaya Therapeutics is a biotech company focused on developing gene therapy and regenerative medicine for the treatment of heart disease. This is one of the most cutting-edge fields of science. This chart shows the growth of an elite team of scientists working to develop methods that can not only treat, but potentially cure, severe heart diseases.
Number of employees in the market as a whole
Tenaya Therapeutics is a biotech company developing drugs for heart disease. Although their operations are highly specialized, the overall economic environment, illustrated in this chart, is important. A stable labor market fosters investment in research-intensive industries, allowing companies like Tenaya to raise capital for costly clinical trials.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company TNYA (TNYA)
Tenaya Therapeutics is a biotech company working on gene therapy for heart disease. This chart represents the market's bet on a scientific breakthrough. Astronomical market capitalization per employee is typical for research-stage companies. Each scientist on the team potentially creates technology worth billions of dollars, and the market is taking this into account.
%20of%20the%20company%20TNYA%20(TNYA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-TNYA-TNYA&v=1772646781324 "Chart of market capitalization per employee (in thousands of dollars) of the company TNYA (TNYA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Heart
Tenaya Therapeutics is a biotech company focused on developing gene therapies for heart disease. Its core assets are its research and intellectual property. This chart shows how highly the market values its potential relative to its small research staff compared to the biotech industry average.
%20by%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Heart&v=1772646781381 "Market capitalization per employee (in thousands of dollars) by market segment - Heart")
Market capitalization per employee (in thousands of dollars) for the overall market
Tenaya Therapeutics is a biotech company developing gene therapy for heart disease. For a clinical-stage biotech, this metric reflects scientific potential. Its high market capitalization per employee reflects investors' assessment of the likelihood of success for its cutting-edge research, which could transform medicine.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772646781408 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company TNYA (TNYA)
Tenaya is a preclinical biotech company focused on gene therapy for cardiovascular diseases. This graph shows a negative value for them. The company has no revenue, and its research staff is fully dedicated to R&D. Every employee represents an investment in a breakthrough technology that will require hundreds of millions of dollars to reach the market.
%20Chart%20TNYA%20(TNYA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-TNYA-TNYA&v=1772646781437 "Company Profit Per Employee (in thousands of dollars) Chart TNYA (TNYA)")
Profit per employee (in thousands of dollars) in the market segment - Heart
Tenaya Therapeutics is a clinical-stage biotech company focused on gene therapy for heart disease. Like many biotech R&D companies, Tenaya is currently investing in science rather than generating revenue. This chart shows the industry average profit per employee. For Tenaya, it serves as a benchmark, demonstrating the potential effectiveness the company aims for if its developments are successful.
%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Heart&v=1772646781492 "Chart of profit per employee (in thousands of dollars) in the market segment - Heart")
Profit per employee (in thousands of dollars) for the market as a whole
Tenaya Therapeutics is a biotech company working at the cutting edge of science. They are focused on developing gene therapy and cell regeneration for the treatment of severe heart diseases. This is pure R&D. This chart doesn't show profit, but rather the enormous investment (R&D costs) per scientist trying to create a drug that can "fix" the heart.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772646781495 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee TNYA (TNYA)
Tenaya Therapeutics is a biotech company developing gene therapy for heart disease. Currently, the graph reflects the intensive research stage. Future revenue growth per employee will directly depend on the success of clinical trials and the company's ability to bring its innovative and potentially expensive drugs to market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-TNYA-TNYA&v=1772646781526 "Sales chart per company employee TNYA (TNYA)")
Sales per employee in the market segment - Heart
Tenaya Therapeutics is a clinical-stage biotech focused on gene therapy for cardiovascular diseases. Like Anteris, they currently have no commercial revenue. This chart reflects their current stage: a significant team of highly skilled scientists but zero sales, which stands in stark contrast to the pharma industry average.
Sales per employee for the market as a whole
Tenaya Therapeutics is a biotech company working at the cutting edge of science. Their goal is to develop gene therapies and drugs for cardiac muscle regeneration. This is a pure R&D business. This graph will likely show zero revenue, as their elite team of scientists is in the clinical research stage, without a commercial product yet.
Short shares by company, segment and market as a whole
Shares shorted by company TNYA (TNYA)
Tenaya (TNYA) is a clinical-stage biotech focused on developing gene therapies and other treatments for cardiovascular disease. This chart shows the volume of bearish bets. The high short interest reflects investor skepticism about their complex scientific platform, the expectation of clinical trial failure, or the enormous research costs.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-TNYA-TNYA&v=1772646781554 "Short Shares Chart for the Company TNYA (TNYA)")
Shares shorted by market segment - Heart
Tenaya (TNYA) is a clinical-stage biotech focused on developing gene therapy for heart disease. This chart illustrates the general skepticism in the gene therapy sector. It summarizes the bearish bets, reflecting the enormous risks and investor doubts about the success of clinical trials across this entire niche.
Shares shorted by the overall market
Tenaya Therapeutics is a clinical-stage biotech developing gene therapy for heart disease. Its valuation is 100% driven by science. However, when fear mounts in the market (as in this chart), the risk-off sentiment makes it incredibly difficult for cash-burning biotechs to attract new funding.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator TNYA (TNYA)
Tenaya Therapeutics (TNYA) is a biotech company focused on developing gene therapies and small-molecule drugs for rare heart diseases. This chart measures hype. It shows "overheated" (above 70) due to positive preclinical or early clinical trial data, or "oversold" (below 30) due to R&D delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-TNYA-TNYA&v=1772646781623 "RSI 14 indicator chart for the company's stock TNYA (TNYA)")
RSI 14 Market Segment - Heart
Tenaya (TNYA) is a biotech company tackling one of the most challenging goals: developing gene therapy to treat heart failure. It's high-risk science. This chart tracks the collective sentiment in the Cardiology/Genomic Technologies sector. It shows when the entire industry is overheated by hype around breakthroughs or oversold by setbacks.
RSI 14 for the overall market
Tenaya (TNYA) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TNYA (TNYA)
Tenaya Therapeutics is a biotech company developing gene therapy and precision medicine for the treatment of heart failure. Because the company is in the clinical stage and has no revenue, this chart is especially important: it shows the average price target Wall Street analysts have for TNYA based on their assessment of its scientific potential.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TNYA-TNYA&v=1772646781669 "A chart showing analyst consensus forecasts for the expected stock price. TNYA (TNYA)")
The difference between the consensus estimate and the actual stock price TNYA (TNYA)
Tenaya Therapeutics is a clinical-stage biotech company betting all-in on gene therapy for heart failure. Their success is a binary event, dependent on trial data. This chart reflects analyst confidence in their R&D platform and the potential of their drugs. It shows the gap between the consensus estimate for this "blockbuster" and the current, speculative price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TNYA-TNYA&v=1772646781671 "A chart showing the difference between the consensus forecast and the actual stock price. TNYA (TNYA)")
Analyst consensus forecast for stock prices by market segment - Heart
Tenaya (TNYA) is a biotech company betting on gene therapy to treat heart failure. This is cutting-edge, but high-risk R&D. The success of such companies depends on the overall risk appetite of investors. This chart shows what analysts expect from the entire biotech sector: whether they believe in breakthroughs or expect a funding winter.
Analysts' consensus forecast for the overall market share price
Tenaya Therapeutics is a biotech company working on gene therapy and drugs for the treatment of heart failure. This is one of the most complex and capital-intensive areas of medicine. This chart shows the overall risk appetite. For Tenaya, whose value is an option on a future scientific breakthrough, overall market optimism (risk appetite) is critical to funding multi-year, expensive clinical trials.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index TNYA
Tenaya Therapeutics is a biotech company that has taken on one of the most challenging targets: treating heart failure with gene therapy. This is a pure R&D bet on breakthrough science. This chart is a comprehensive indicator. It doesn't reflect current profits, but rather a speculative assessment of their scientific progress, market confidence in their platform, and their chances in this multi-billion-dollar but highly complex disease.
AKIMA Market Segment Index - Heart
Tenaya Therapeutics is a biotech company focused on one of the most complex areas of medicine: treating heart failure with gene therapy. This chart shows the segment average. It allows investors to assess how Tenaya's risky but potentially revolutionary scientific platform compares to the industry average.
The AKIM Index for the overall market
Tenaya Therapeutics is a biotech company focused on combating genetic and acquired heart diseases. It's at the cutting edge of science. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding such complex and capital-intensive ventures.
